EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SILO Pharma's Enterprise Value is $-1.24 Mil.
SILO Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $-4.64 Mil. Therefore, SILO Pharma's EV-to-FCF for today is 0.27.
The historical rank and industry rank for SILO Pharma's EV-to-FCF or its related term are showing as below:
SILO'
s EV-to-FCF Range Over the Past 10 Years
Min: -9708 Med: -3.61 Max: 180.96
Current: 0.27
During the past 13 years, the highest EV-to-FCF of SILO Pharma was 180.96. The lowest was -9708.00. And the median was -3.61.
SILO's EV-to-FCF is ranked better than 85.57% of 388
companies
in the Biotechnology industry
Industry Median: 8.68
vs SILO: 0.27
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for SILO Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SILO Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where SILO Pharma's EV-to-FCF falls into.
SILO Pharma's current Enterprise Value is $-1.24 Mil.
SILO Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (NAS:SILO) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SILO Pharma's PE Ratio (TTM) for today is calculated as:
SILO Pharma's share price for today is $0.595.
SILO Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SILO Pharma EV-to-FCF Related Terms
Thank you for viewing the detailed overview of SILO Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SILO has been successfully added to your 